Please sign in to follow a disease.

Breast intraductal proliferative lesion

MONDO:0004007

A group of non-invasive epithelial proliferations that occur in the ductal system of the breast. The vast majority of cases arise in the terminal ductal lobular units. This category includes atypical ductal hyperplasia, usual ductal hyperplasia, flat epithelial atypia, and ductal carcinoma in situ. There is an increased risk for subsequent development of invasive breast carcinoma.

Also known as: DIN, ductal intraepithelial neoplasia, intraductal proliferative lesion, intraductal proliferative lesion of the breast, mammary intraepithelial neoplasia, ductal type

1594 clinical trials for this condition and its sub-types, 8 tagged with Breast intraductal proliferative lesion itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Intraductal breast neoplasm (155)

Sub-types of Breast intraductal proliferative lesion

Ductal breast carcinoma in situ 152 trials
1 sub-type
- Intraductal cribriform breast adenocarcinoma 0 trials
Flat ductal epithelial atypia 3 trials
Usual ductal breast hyperplasia 0 trials

Including sub-types (1594) Tagged with Breast intraductal proliferative lesion (8)

Trials to join now! 1 Not yet recruiting 2 Not yet finished but already full! 2 Completed 2 Terminated 1

Could a lower tamoxifen dose prevent breast cancer in high-risk women?

Prevention Recruiting now

This study is for premenopausal women at higher-than-average risk for breast cancer. It tests whether a low dose of tamoxifen can safely reduce breast density, which is linked to cancer risk. About 200 women will take tamoxifen, and doctors will adjust the dose if needed to get t…

Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention

Last updated Jul 29, 2026 00:00 UTC

Breast intraductal proliferative lesion

Where it sits in the disease tree

Could a lower tamoxifen dose prevent breast cancer in high-risk women?